

Regulatory Announcement

[Go to market news section](#)



Company Omega Diagnostics Group PLC
TIDM ODX
Headline Trading Statement
Released 11:41 02-Apr-09
Number 0038Q11



RNS Number : 0038Q
 Omega Diagnostics Group PLC
 02 April 2009

Omega Diagnostics Group Plc ("Omega")

Trading Update

Omega, the AIM listed medical diagnostics company, announces that revenue for the year ended 31 March 2009 is £5.44m, some 56% ahead of last year's figure (31 March 2008: £3.49m). On a full like for like basis, turnover has increased by 20% combined, and individually across all three trading entities, where the figures in brackets for Genesis Diagnostics and Cambridge Nutritional Sciences represent the full 12-month comparative:

	31 March 2009	31 March 2008	% increase
Omega Diagnostics (ODL)	£2.28m	£2.08m	+9.5%
Genesis Diagnostics	£2.51m	£1.07m (£1.90m)	+133.9% (+32.6%)
Cambridge Nutritional Sciences	£0.65m	£0.34m (£0.56m)	+93.9% (+16.5%)
TOTAL	£5.44m	£3.49m (£4.54m)	+55.9% (+20.0%)

ODL has seen growth in most of its regions around the world, particularly in Africa/Middle East and Asian regions. Genesis has seen growth fuelled mainly by the roll-out into a number of territories of its microarray-based Genarray™ assay system for food intolerance, where evaluations are on-going which are expected to lead to increased sales of reagent kits going forward. CNS has benefited from launching the Food Detective™ kit into a number of European territories and from an increase in sales from its Foodprint™ laboratory testing service.

Profit before tax (and before share based payments, exceptional costs and amortisation of intangible assets) is expected to be in line with market expectations.

The outlook for the new financial year is encouraging as we expect to continue to widen the roll-out of the Genarray™ system and to launch Food Detective™ into other new markets and we look forward to providing an update on progress when the full year results are announced in early July 2009.

Further enquiries:

Omega Tel: 01259 763 030
Diagnostics Plc
Andrew
Shepherd, Chief
Executive
Kieron Harbinson, www.omegadiagnostics.com
Group Finance
Director

Cenkos Tel: 020 7397 8900
Securities plc
Nick Wells
Andy Roberts
Elizabeth
Bowman

Parkgreen Tel: 020 7933 8787
Communications

Limited

Paul McManus

Mob: 07980 541 893

paul.mcmanus@parkgreenmedia.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

TSTFGGGDGZLGLZM

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2009 London Stock Exchange plc. All rights reserved